The immune checkpoint blockade (ICB) therapy has revolutionized
the field of cancer treatment, while low response rates and systemic
toxicity limit its clinical outcomes. With the rapid advances in nanotechnology
and materials science, various types of biomaterials have been developed
to maximize therapeutic efficacy while minimizing side effects by
increasing tumor antigenicity, reversing immunosuppressive microenvironment,
amplifying antitumor immune response, and reducing extratumoral distribution
of checkpoint inhibitors as well as enhancing their retention within
target sites. In this review, we reviewed current design strategies
for different types of biomaterials to augment ICB therapy effectively
and then discussed present representative biomaterial-assisted immune
modulation and targeted delivery of checkpoint inhibitors to boost
ICB therapy. Current challenges and future development prospects for
expanding the ICB with biomaterials were also summarized. We anticipate
this review will be helpful for developing emerging biomaterials for
ICB therapy and promoting the clinical application of ICB therapy.